Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3212]

ASH 2018: Researchers identify mutation in BCL2 protein that causes resistance to venetoclax

ASH 2018: Researchers identify mutation in BCL2 protein that causes resistance to venetoclax

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

Last Month in Oncology with Dr. Bishal Gyawali: November 2018

Last Month in Oncology with Dr. Bishal Gyawali: November 2018

ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial

ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell...

ASH 2018: Machine learning-based model improves prognosis accuracy for myelodysplastic syndromes

ASH 2018: Machine learning-based model improves prognosis accuracy for myelodysplastic syndromes

ASH 2018: Rapid genetic screening shows feasibility of precision medicine for acute myeloid leukaemia

ASH 2018: Rapid genetic screening shows feasibility of precision medicine for acute myeloid leukaemia

ASH 2018: Disruptions in the gut microbiota before hematopoietic cell transplantation associated with worse outcomes

ASH 2018: Disruptions in the gut microbiota before hematopoietic cell transplantation associated with worse...

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

More from ecancer